BPC-157 + GHK-CU + TB-500

This catalog entry combines BPC-157, GHK-CU, and TB-500, three peptides that show up in experimental and wellness discussions around tissue repair, cosmetic applications, and anti-inflammatory themes.

The combination SKU is organizational: it indicates that these peptides are packaged together, not that combined use is supported by strong clinical evidence or professional guidelines.

At a high level, combination products like this aim to bundle multiple mechanistic ideas:

• BPC-157: discussed in preclinical work for potential effects on vascular, inflammatory, and gastrointestinal integrity

• TB-500 (thymosin beta-4 fragment): associated in models with actin dynamics, cell migration, and tissue repair

• GHK-CU: a copper-binding peptide often referenced in cosmetic and wound- healing contexts

The actual clinical significance of combining all three in humans is not well defined, and rigorous combination studies are limited.

In most regulated settings, these peptides—alone or in combination—do not have approved indications for tissue repair, cosmetic, or anti-inflammatory use. They are more commonly encountered in research channels or grey-market wellness spaces.

Any proposed use of combination products should be approached as experimental and evaluated carefully against local laws and ethical standards.

Described effects for single agents include local injection-site reactions, gastrointestinal symptoms, headache, and nonspecific fatigue. Long-term safety, especially with multi-peptide regimens, is poorly characterized.

Because of these gaps, conservative interpretation and reliance on up-to-date, peer-reviewed evidence are especially important.

This blend combines tissue repair peptides. Dosing is often calculated based on the BPC-157 content.

This information summarizes commonly discussed research practices.

This trio is the blend widely marketed as "GLOW" — a vendor marketing name, not a clinical designation. Vials are sold pre-mixed at vendor-chosen ratios (10/10/10 mg splits and weighted variants both circulate), and no study has compared any ratio against another. Adding the anti-inflammatory peptide KPV produces the four-peptide blend marketed as "KLOW"; the two-peptide core is sold as BPC-157 + TB-500. Pre-mixing three structurally unrelated peptides — one carrying a copper ion — raises stability questions no one has published data on.

Most systematic work examines BPC-157, thymosin beta-4–related peptides, and GHK-CU separately. Formal evidence on triple combinations is sparse.

As a result, high-level summaries like this are best used as orientation to concepts, not as a basis for recommending combination use.

For deeper dives on this peptide, see:

• BPC-157 + GHK-CU + TB-500 benefits and areas of interest
• BPC-157 + GHK-CU + TB-500 side effects and safety context
• BPC-157 + GHK-CU + TB-500 dosing concepts (educational)
• BPC-157 + GHK-CU + TB-500 research and evidence overview

What is the "GLOW" peptide blend? "GLOW" is a marketing name vendors use for a pre-mixed vial of BPC-157, GHK-Cu, and TB-500, pitched as a combined recovery-and-skin formula. No published study uses the name, defines a standard ratio, or has tested the three peptides together in any model.

Is there evidence the three work better together? No — and the nearest evidence points the other way. A 2026 randomized rat tendon study of two of the three components found TB-500 alone significantly improved healing, BPC-157 alone did not reach significance, and the combination "did not confer additional benefits compared to either agent alone" (Biçer et al., Jt Dis Relat Surg 2026). No study at all includes the GHK-Cu arm of the blend.

Isn't GHK-Cu proven for skin? Its human evidence is topical. The comprehensive 2018 review documents cosmetic cream trials and extensive cell and animal work, with plasma GHK declining from about 200 ng/mL at age 20 to 80 ng/mL by 60 — but no human injection trials (Pickart & Margolina, Int J Mol Sci 2018). Results from creams do not automatically transfer to a syringe.

Is any component approved or human-proven? No. A 2025 review states there are "no completed clinical studies describing [BPC-157's] efficacy in humans" (Józwiak et al., Pharmaceuticals 2025); thymosin β4's human trials targeted wounds and corneal injury without producing an approved drug (Goldstein et al. 2012); and BPC-157 sits on the FDA's compounding safety-risk list (FDA).

Can tested athletes use this blend? Not without sanction risk: TB-500 is named in category S2.3 of the WADA Prohibited List (prohibited at all times), and BPC-157 is captured by the S0 non-approved-substances category.